Terms: = Lymphoma AND FBXO11, MGC44383, 80204, ENSG00000138081, Q86XK2, VIT1, UG063H01, PRMT9, FLJ12673, FBX11
11 results:
1. Higher 13-Gene-Estimated TMB Detected from Plasma ctDNA is Associated with Worse Outcome for T-Cell lymphoma Patients.
Chen C; Huang L; Chen Z; Ou Q; Liu S; Jiang X; Chen F; Wei X; Guo H; Shao Y; Zeng C; Li Y; Li W
Adv Biol (Weinh); 2023 Dec; 7(12):e2300042. PubMed ID: 37658484
[TBL] [Abstract] [Full Text] [Related]
2. Frequent mutations of fbxo11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.
Pighi C; Cheong TC; Compagno M; Patrucco E; Arigoni M; Olivero M; Wang Q; López C; Bernhart SH; Grande BM; Poggio T; Langellotto F; Bonello L; Dall'Olio R; Martínez-Martín S; Molinaro L; Francia di Celle P; Whitfield JR; Soucek L; Voena C; Calogero RA; Morin RD; Staudt LM; Siebert R; Zamò A; Chiarle R
Blood Adv; 2021 Dec; 5(23):5239-5257. PubMed ID: 34625792
[TBL] [Abstract] [Full Text] [Related]
3. Genetic features of precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.
Yoshida M; Tomizawa D; Yoshimura S; Osumi T; Nakabayashi K; Ogata-Kawata H; Ishiwata K; Sato-Otsubo A; Kimura Y; Ito S; Matsumoto K; Deguchi T; Kiyokawa N; Yoshioka T; Hata K; Kato M
Cancer Rep (Hoboken); 2022 Jul; 5(7):e1545. PubMed ID: 34472720
[TBL] [Abstract] [Full Text] [Related]
4. Loss-of-function of Fbxo10, encoding a post-translational regulator of BCL2 in lymphomas, has no discernible effect on BCL2 or B lymphocyte accumulation in mice.
Masle-Farquhar E; Russell A; Li Y; Zhu F; Rui L; Brink R; Goodnow CC
PLoS One; 2021; 16(4):e0237830. PubMed ID: 33914737
[TBL] [Abstract] [Full Text] [Related]
5. Constitutional 2p16.3 deletion including MSH6 and fbxo11 in a boy with developmental delay and diffuse large B-cell lymphoma.
van Engelen N; van Dijk F; Waanders E; Buijs A; Vermeulen MA; Loeffen JLC; Kuiper RP; Jongmans MCJ
Fam Cancer; 2021 Oct; 20(4):349-354. PubMed ID: 33811277
[TBL] [Abstract] [Full Text] [Related]
6. CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation.
Jiang C; Trudeau SJ; Cheong TC; Guo R; Teng M; Wang LW; Wang Z; Pighi C; Gautier-Courteille C; Ma Y; Jiang S; Wang C; Zhao B; Paillard L; Doench JG; Chiarle R; Gewurz BE
Cell Rep; 2019 Jul; 28(5):1307-1322.e8. PubMed ID: 31365872
[TBL] [Abstract] [Full Text] [Related]
7. Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation.
Sun D; Stopka-Farooqui U; Barry S; Aksoy E; Parsonage G; Vossenkämper A; Capasso M; Wan X; Norris S; Marshall JL; Clear A; Gribben J; MacDonald TT; Buckley CD; Korbonits M; Haworth O
Cell Rep; 2019 Apr; 27(5):1461-1471.e4. PubMed ID: 31042473
[TBL] [Abstract] [Full Text] [Related]
8. Identification of a tumor suppressor network in T-cell leukemia.
Nagel S; Pommerenke C; Meyer C; Kaufmann M; MacLeod RAF; Drexler HG
Leuk Lymphoma; 2017 Sep; 58(9):2196–2207. PubMed ID: 28142295
[TBL] [Abstract] [Full Text] [Related]
9. fbxo11 inactivation leads to abnormal germinal-center formation and lymphoproliferative disease.
Schneider C; Kon N; Amadori L; Shen Q; Schwartz FH; Tischler B; Bossennec M; Dominguez-Sola D; Bhagat G; Gu W; Basso K; Dalla-Favera R
Blood; 2016 Aug; 128(5):660-6. PubMed ID: 27166359
[TBL] [Abstract] [Full Text] [Related]
10. Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma.
Parry M; Rose-Zerilli MJ; Gibson J; Ennis S; Walewska R; Forster J; Parker H; Davis Z; Gardiner A; Collins A; Oscier DG; Strefford JC
PLoS One; 2013; 8(12):e83244. PubMed ID: 24349473
[TBL] [Abstract] [Full Text] [Related]
11. fbxo11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.
Duan S; Cermak L; Pagan JK; Rossi M; Martinengo C; di Celle PF; Chapuy B; Shipp M; Chiarle R; Pagano M
Nature; 2012 Jan; 481(7379):90-3. PubMed ID: 22113614
[TBL] [Abstract] [Full Text] [Related]
